Fair Drugs Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 44 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 19.42%
- Profit Growth 96.06%
- Ebitda 108.11%
- Net Worth -0.66%
- Total Assets -9.39%
About Fair Drugs Laboratories
Fair Drugs Laboratories Pvt Ltd (FDLPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 February 1981 and has a history of 44 years. Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Kamalendu Banerjee and Aradhya Banerjee serve as directors at the Company.
Company Details
-
Location
24 Parganas, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231WB1981PTC033346
-
Company No.
033346
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Feb 1981
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Fair Drugs Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamalendu Banerjee
|
Whole-Time Director | 01-Dec-2017 | Current |
|
Aradhya Banerjee
|
Director | 15-Jun-2019 | Current |
Financial Performance of Fair Drugs Laboratories.
Fair Drugs Laboratories Pvt Ltd, for the financial year ended 2019, experienced significant growth in revenue, with a 19.42% increase. The company also saw a substantial improvement in profitability, with a 96.06% increase in profit. The company's net worth dipped by a decrease of 0.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fair Drugs Laboratories?
In 2019, Fair Drugs Laboratories had a promoter holding of 57.30% and a public holding of 42.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fair Drugs Laboratories?
Fair Drugs Laboratories has a workforce of 12 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fair Drugs Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fair Drugs Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
